People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Prolacta Bioscience Inc | — | Biotechnology | Series B | $64.7M | $353.6M | 2018 |
Alyson Fuller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alyson Fuller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frank Foster | 1 | 12 |
| John Shields | 1 | 6 |
| David Brailer | 1 | 4 |
| Dan Janney | 1 | 4 |
| David Dreyer | 1 | 3 |
| Ned Brown | 1 | 3 |
| Frank D. Foster | 1 | 2 |
| Martin Sutter | 1 | 2 |
| Victoria Niklas | 1 | 2 |
| Ernie D. Strapazon | 1 | 1 |
| Sally Crawford | 1 | 1 |
| Ned D. Brown | 1 | 1 |
| Alison Kiley | 1 | 1 |
| Scott Elster | 1 | 1 |
| John D. Bacich, Jr. | 1 | 1 |
| Joshua D. Saipe | 1 | 1 |
| Tami Ciranna | 1 | 1 |
| Mark Hannon | 1 | 1 |
| Ernie Strapazon | 1 | 1 |
| John Bacich Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.